Inactivation of the apoptosis effector Apaf-1 in malignant melanoma

By M. Soengas, P. Capodieci, D. Polsky, J. Mora, Manel Esteller, Ximena Opitz-Araya, R. Mccombie, J. Herman, W. Gerald, Y. Lazebnik and 2 more. Nature, 2001

1,008 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/0603246cd4b3180ff4e867a20e64e57f3f46d175

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

Citations in the corpus

A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer (2002, background): “5 uk AA457731 SNARE protein YKT6 6 uk AA419251 interferon induced transmembrane protein 1 (9-27) IFITM1 11 uk N48178 KIAA0403 protein 6 uk AA027147 hypothetical protein MGC3040 3 uk H18646 hypothetical protein FLJ10697 10 uk AA013268 Homo sapiens mRNA containing (CAG)4 repeat, clone CZ-CAG-7 UK uk A”
Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks (2004, background): “The APAF-1 gene is frequently hypermethylated and therefore silenced in melanoma cells (Soengas et al., 2001), and human leukemia (Fu et al., 2003).”
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer (2002, background): “cgi?l=841">caspase-8 , have been correlated with cancer onset and progressio”
CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future (2002, background): “5- aza-2’-deoxycytidine alone can even induce reexpression of certain silenced tumor suppressor genes that do not have an apparent CpG island hypermethylation, such as APAF-1 (Soengas et al., 2001).”
Apoptosis A Link between Cancer Genetics and Chemotherapy (2002, background): “Tumor Cells Evade Death-Receptor-Inducedactivation, is commonly observed in human tumors (De- veraux and Reed, 1999; Soengas et al., 2001; Beere and Apoptosis Tumorigenic disruptions in the death-receptor pathwayGreen, 2001).”
Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. (2006, background): “2005) in melanomas, terminal differentiation may not be an option, and apoptosis prevented by loss of APAF1 for example (Soengas et al. 2001).”
Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies (2016, background): “Other examples of alteration of the intrinsic pathway include reduced expression of the basic component of the apoptosome, Apaf-1, in melanomas [71,72], as result of promoter aberrant methylation.”
Pathways of apoptotic and non-apoptotic death in tumour cells (2004, background): “Similarly, loss of APAF1 function seems to be important for the oncogenic transformation of melanoma and ovarian cancer cell line”
Clinical translation of angiogenesis inhibitors (2002, background): “Tumour cells also become resistant to chemotherapy-induced apoptosi”
Melanoma biology and new targeted therapy (2007, background): “Finally, the frequent silencing of apoptotic peptidase activating factor-1 (APAF-1) in advanced melanoma”